SCHEDULE 13G: T. Rowe Price Associates Discloses 5.3% Passive Stake in MoonLake Immunotherapeutics
Beneficial Ownership Report
T. Rowe Price Associates, Inc. has reported a passive beneficial ownership of 5.3% of MoonLake Immunotherapeutics' common stock as of December 31, 2024.
Summary
- T. Rowe Price Associates, Inc. filed a Schedule 13G, indicating beneficial ownership of MoonLake Immunotherapeutics common stock.
- As of December 31, 2024, T. Rowe Price beneficially owned 3,343,643 shares of MoonLake Immunotherapeutics common stock.
- This represents 5.3% of the total outstanding common stock of MoonLake Immunotherapeutics.
- T. Rowe Price holds sole voting power over 3,309,301 shares and sole dispositive power over 3,343,643 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by a reputable institutional investor like T. Rowe Price is generally viewed positively by the market, indicating confidence in the company's long-term prospects.
Positives
- A significant institutional investor like T. Rowe Price taking a 5.3% stake can be viewed as a vote of confidence in MoonLake Immunotherapeutics.
- The passive nature of the investment (Rule 13d-1(b)) suggests a long-term investment strategy rather than an activist intent.
Future Outlook
NA
Industry Context
This filing indicates growing institutional interest in MoonLake Immunotherapeutics, a company operating in the biotechnology and immunotherapy sector. The investment by a major asset manager like T. Rowe Price suggests a positive outlook on the company's potential within the competitive pharmaceutical landscape.
Stakeholder Impact
- Shareholders may perceive this as a positive signal, potentially increasing investor confidence and attracting further institutional investment.
- The company's management might view this as validation of their strategy and potential for long-term growth.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership threshold crossed) |
| 02/14/2025 | Date of signature for the Schedule 13G filing |
Keywords
MoonLake Immunotherapeutics, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Immunotherapy, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.